Zejing Pharmaceuticals: In a phase II dose optimization clinical study of ZG006 monotherapy in patients with refractory advanced small cell lung cancer, the optimal response rates for the 10 mg Q2W group and the 30 mg Q2W group were 60.0% and 66.7%, respectively.

Zejing Pharmaceuticals announced that the clinical research data and the latest progress of the company's independently developed new drug Alveltamig will be released at the 2025 European Society for Medical Oncology Asian Congress. In the phase II dose optimization clinical research of ZG006 monotherapy in patients with refractory advanced small cell lung cancer, the best response rates for the 10 mg Q2W group and the 30 mg Q2W group were 60.0% and 66.7%, respectively, with confirmed response rates of 53.3% and 56.7%, and disease control rates of 73.3% in both groups. The median progression-free survival periods were 7.03 months and 5.59 months, respectively, with immature median durations of response in both groups. The 6-month duration of response rates were 71.8% and 69.5%, and the 9-month duration of response rates were 61.6% and 55.6%. The median overall survival times were immature in both groups, with 6-month overall survival rates of 83.2% and 76.7%, and 12-month overall survival rates of 69.1% and 58.2%.